How often should Cemiplimab be used in a cycle?

Cemiplimab (Cemiplimab) is a PD-1 immune checkpoint inhibitor. Its administration method is significantly different from traditional chemotherapy. It emphasizes fixed intervals, long-term maintenance and the stability of immune activation rhythm. According to overseas official information, whether it is for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma, advanced basal cell carcinoma, or non-small cell lung cancer, the recommended dosing cycle is mainly "intravenous infusion once every three weeks". This setting is based on the duration of immune regulation, metabolic cycle and long-term safety assessment of the drug in the body.

For skin-derived malignant tumors such as cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), the treatment principle emphasizes the continuous activation of the body's immune response, so intravenous infusion of 350 mg every three weeks is often used, and treatment continues until the disease progresses on imaging, unacceptable adverse reactions occur, or for up to two years. In immunotherapy, the course of treatment is usually not set to a strict "several cycles as one round" like chemotherapy. Instead, the status is regularly evaluated to determine whether it should continue. If patients experience immune-related reactions, their medication may need to be adjusted or suspended based on tolerance, but the overall dosing rhythm is still based on three weeks.

In the treatment of non-small cell lung cancer (NSCLC), cimepilimab is also administered once every three weeks. Overseas guidelines emphasize that this constant rhythm can maintain continuous immune activation, thereby stabilizing the cancer control effect. The treatment endpoint is also mainly based on disease progression or uncontrollable toxicity, and no clear cycle termination point is set. In actual treatment, doctors will make a comprehensive judgment based on image changes, immune-related adverse reactions, and the patient's overall tolerance to determine the length of treatment.

Since the treatment rhythm of immune drugs needs to remain stable, delaying or arbitrarily adjusting the interval may affect the immune activation effect. Therefore, patients should strictly follow the basic cycle of "once every three weeks" and regularly review liver and kidney function, thyroid indicators and immune-related symptoms.

Reference materials:https://www.libtayohcp.com/